featured
Efficacy and Safety of 80-mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR-Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM)
J. Clin. Oncol 2024 Jun 03;[EPub Ahead of Print], S Park, R Baldry, HA Jung, JM Sun, SH Lee, JS Ahn, YJ Kim, Y Lee, DW Kim, SW Kim, KH Lee, WJ Lee, JW Choi, K Chong, JI Lee, SH Gwon, NH Son, MJ AhnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.